The European Commission has granted in 2008 Jerini AG marketing authorization for its compound Firazyr (R) (Icatibant) in the treatment of acute attacks of hereditary angioedema in all EU countries. Firazyr works by blocking the B2 receptor as an antagonist to the peptide-hormone bradykinin. Bradykinin has been shown to be elevated in HAE patients and responsible for edema formation during HAE attacks. Firazyr has been granted orphan drug status for the symptomatic treatment of acute attacks of angioedema by the European Medicines Agency (EMEA), potentially securing, upon approval, market exclusivity for ten and seven years, respectively. Among the key benefits of Firazyr for patients, are its safety and efficacy profile demonstrated in clinical studies to date, subcutaneous administration, and room temperature stability. Firazyr is authorised since 2008 in Romania and is available as pre-filled syringe.